NuMe Health LLC (New Orleans, La.), a biotechnology company developing evidence-based cobiotic products that modify bacteria in the gastrointestinal (GI) tract, has closed a $1.5 million Series A financing. The round was led by existing investor BVM Capital with participation of company insiders and several new private investors.
NuMe is also initiating a clinical trial of its lead cobiotic product, NM504, designed to support healthy blood glucose levels and metabolic fitness in people with prediabetes. Funds will be used to develop the initial format for the company’s first consumer product, complete the pilot clinical trial, and prepare for a direct-to-consumer launch.
NuMe's initial products are derived from bioactive plant ingredients that promote the growth of specific bacteria with the potential to positively affect metabolic conditions. NuMe was a presenting company at the NCN Fall 2011 Investor Meeting in Los Angeles.
Disclaimer: NCN does not warrant the accuracy, reliability, or timeliness of any NCN news item. Before relying on any NCN News item the information should be independently verified.
For more finance and investment information, visit Nutrition Capital Network news.